Microbot Medical Inc. (NASDAQ: MBOT) has signed a Letter of Agreement with Sanmina Corporation to manufacture its LIBERTY Endovascular Robotic System, according to a company statement released June 30, 2026.

The LIBERTY System is FDA-cleared as a single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot said the agreement with Sanmina, a global contract manufacturer with sites across multiple regions, is intended to serve as a second manufacturing site, diversify production capabilities, and support cost reduction efforts.

The company said it expects the arrangement to improve operating efficiencies, lower costs, and expand gross margins. Microbot cited growing utilization among accounts across the eastern U.S., recent regulatory clearance in Israel, and ongoing efforts to obtain CE Mark certification and registrations in additional markets as factors driving the need for increased capacity.

"As the pace of adoption continues to gain momentum, with several accounts across the Eastern U.S. increasing their utilization of the LIBERTY System," said Michal Ahuvia, Director of Operations at Microbot Medical, "we believe Sanmina will allow us to increase our manufacturing capacity and enable us to drive greater efficiency while addressing market demand for the foreseeable future."

Asaf Shemesh, CEO of Sanmina Israel, said the company is "confident in the value of this partnership" and is ready to support the LIBERTY System as it pursues its strategic objectives.

Microbot also said it plans to expand its sales presence to the western U.S. later in 2026. The company described Sanmina as one of the largest contract manufacturers globally, with facilities positioned to support anticipated production scaling over the next several years.